Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Misses on Revenue, Stock Up 2.39%

Corvus Pharmaceuticals reported an EPS of $-0.14, with no revenue figures disclosed. Despite the lack of detailed guidance or commentary, the stock rose by 2.39%, indicating that investors may be reacting positively to the EPS figure or other underlying factors not disclosed in the earnings report.